FDA Approved: LEQEMBI — Supplemental Application (Eisai Inc.)

View source ↗

Summary

FDA approves a supplemental application for LEQEMBI (lecanemab) submitted by Eisai Inc., resulting in labeling changes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• LEQEMBI (lecanemab)

Snippet

SUPPL AP for LEQEMBI (LECANEMAB)